Newswise — Old Westbury, N.Y. (June 25, 2014) –Administering low doses of a thyroid hormone to rats with diabetes helps restore hormone levels in their hearts and prevented deterioration of heart function and pathology, according to a new study by NYIT College of Osteopathic Medicine Professor and Biomedical Sciences Chair A. Martin Gerdes.
The study, published in the online edition of Molecular Medicine provides the first clear indication that low thyroid hormone levels in cardiac tissue of diabetic individuals may be the major cause of their associated heart disease, says Gerdes.
The study finds that diabetes triggers low thyroid levels that contribute to heart failure. In animal models, Gerdes and colleagues found that administering low doses of the active form of thyroid hormone, T3, prevented the progression of heart disease.
“This treatment prevented the abnormal changes in gene expression, tissue pathology, and heart function,” said Gerdes.
The most recent study builds on a growing body of research by Gerdes and others that links low thyroid hormone levels in heart tissue to heart failure. The research was funded by the National Institutes of Health and the American Diabetes Association. Previous studies, published in the Journal of Translational Medicine and Circulation: Arrhythmia and Electrophysiology, have demonstrated that hypertension and heart attacks also trigger low cardiac thyroid hormone levels and contribute to heart disease.
“The clinical implications are profound and far-reaching because it suggests that the heart disease associated with diabetes may be easily preventable,” Gerdes says of his recent research. “And importantly, the dose we gave of T3 hormone did not significantly change the serum (blood) thyroid hormone levels but it was enough to make all the difference in the heart tissue.”
An individual’s thyroid levels are usually measured by blood tests. But Gerdes has noted that thyroid hormone levels in cardiac tissue do not necessarily correspond with blood test readings of thyroid levels. An individual with heart disease and low cardiac tissue thyroid hormone levels may have normal blood test results, in part because the blood is diluted about twenty-fold once it leaves the heart and joins the rest of circulating blood in the body. Yet, his research has consistently found that low-dose thyroid hormone replacement may be a safe and effective therapy, and Gerdes says it would cost only pennies per day to help humans suffering from heart disease.
“A low thyroid condition can cause heart failure by itself,” says Gerdes. “The fundamental question we should be asking about patients with heart failure is: how much is due to the diagnosed disease and how much is due to low thyroid levels in the heart? There clearly needs to be more awareness with regard to research examining the impact of low thyroid hormone levels in the heart and the role this condition plays in acceleration of heart failure.”
In his animal study, Gerdes and colleagues induced a mild form of diabetes in rats and waited a month for the condition to develop. They then administered low doses of T3 hormone for two months.
Gerdes says more research is needed to identify peripheral serum bio-markers that track with low thyroid hormone levels in the heart. He also says human clinical studies are necessary.
“There’s so much fear of overtreatment (with hormones) and inducing arrhythmias that physicians in general completely avoid treating heart patients with thyroid hormones,” he says. But we have established a clear treatment and monitoring program in this study that is safe and can be used in people.”
Gerdes conducted the research over three years at NYIT. His colleagues include researchers from the University of South Dakota, the Center for Heart and Lung Research at The Feinstein Institute for Medical Research, and the University of Pisa, Italy.
About NYITNew York Institute of Technology (NYIT) offers 90 degree programs, including undergraduate, graduate, and professional degrees, in more than 50 fields of study, including architecture and design; arts and sciences; education; engineering and computing sciences; health professions; management; and osteopathic medicine. A non-profit independent, private institution of higher education, NYIT has 13,000 students attending campuses on Long Island and Manhattan, online, and at its global campuses. NYIT sponsors 11 NCAA Division II programs and one Division I team. Led by President Edward Guiliano, NYIT is guided by its mission to provide career-oriented professional education, offer access to opportunity to all qualified students, and support applications-oriented research that benefits the larger world. To date, nearly 100,000 graduates have received degrees from NYIT. For more information, visit nyit.edu. Contact: Elaine IandoliOffice of Communications516.686.4013